Survivin in lung cancer: a potential target for therapy and prevention-a narrative review
CONCLUSIONS: Nuclear survivin is a potential biomarker for advanced non-small cell lung cancer. It plays a role in determining drug responsiveness and is found to be significantly elevated in cases of resistance to chemotherapy. Multiple compounds and immunization strategies have been identified to impact lung cancer cells; however, they are currently in the early stages of phase I or phase II clinical trials. The substantial promise of survivin-based immunogenicity-focused treatments warrants in-depth investigation and exploration.PMID:38496694 | PMC:PMC10938099 | DOI:10.21037/tlcr-23-621
Source: Cell Research - Category: Cytology Authors: Akhil Goud Pachimatla Robert Fenstermaker Michael Ciesielski Sai Yendamuri Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Chemotherapy | Clinical Trials | Cytology | Databases & Libraries | Genetics | Lung Cancer | Non-Small Cell Lung Cancer | Study | USA Health | Vaccines | Veterinary Vaccinations